|
Accrued
Expenses, summarized by major category, as of June 30, 2021 and December 31, 2020 consist of the following:
Schedule of Accrued Expenses
| |
|
June 30, 2021 |
|
|
December 31, 2020 |
|
| Payroll and incentives |
|
$ |
619 |
|
|
$ |
1,094 |
|
| General and administrative expenses |
|
|
249 |
|
|
|
280 |
|
| Research and development expenses |
|
|
1,055 |
|
|
|
778 |
|
| Deferred revenue and other deferred liabilities * |
|
|
840 |
|
|
|
643 |
|
| Total |
|
$ |
2,763 |
|
|
$ |
2,795 |
|
| * |
At
June 30, 2021, there was an approximately $807 thousand deferred liability under the Cystic Fibrosis Foundation (“CFF”)
agreement and approximately $33 thousand in deferred revenue related to the Genentech Agreement. At December 31, 2020, there was
an approximately $577 thousand deferred liability under the CFF Agreement and approximately $67 thousand in deferred revenue related
to the Genentech Agreement. (See Note 9 – Collaboration Agreements, Licenses and Other Research and Development Agreements).
|
|